Genetic Basis of Familial Cancer Risk: A Narrative Review
Open Access
Abstract
Familial cancers are caused by inherited mutations in specific genes that regulate cell growth, division, and repair. Approximately 5–10% of all cancer cases have a hereditary component, where germline mutations in certain genes increase an individual’s susceptibility to developing cancer. Two major categories of genes are involved in cancer development: tumour suppressor genes and oncogenes. Both play critical roles in regulating normal cell behaviour, and when mutated, they can contribute to uncontrolled cell proliferation and tumour formation. In addition to genetic mutations, epigenetic alterations also play a significant role in familial cancer. Epigenetics refers to changes in gene expression due to DNA methylation, histone modifications, and the dysregulation of non-coding RNAs without alter the underlying DNA sequence. Familial cancer syndromes follow various inheritance patterns, including autosomal dominant, autosomal recessive, X-linked, and mitochondrial inheritance, each with distinct characteristics. Identifying genetic mutations associated with familial cancers is a cornerstone of genetic counselling, which helps individuals and families navigate the complex intersection of genetics, cancer risk, and prevention. Early identification of mutations enables personalized strategies for risk reduction, early detection, and, when applicable, targeted treatment options, ultimately improving patient outcomes.Keywords
All Related Versions
This publication has 98 references indexed in Scilit:
- Epigenetic regulation in cancerMedcomm, 2024
- Genotype–Phenotype Correlations in Autosomal Dominant and Recessive APC Mutation-Negative Colorectal Adenomatous PolyposisDigestive Diseases and Sciences, 2023
- Constitutional BRCA1 Methylation and Risk of Incident Triple-Negative Breast Cancer and High-grade Serous Ovarian CancerJAMA Oncology, 2022
- Multiple primary melanoma in association with other personal and familial cancersCancer Medicine, 2022
- Congenital X‐linked neutropenia with myelodysplasia and somatic tetraploidy due to a germline mutation in SEPT6American Journal of Hematology, 2021
- The genetics of mitochondrial disease: dissecting mitochondrial pathology using multi‐omic pipelinesThe Journal of Pathology, 2021
- Genetic predisposition to prostate cancer: an updateFamilial Cancer, 2021
- Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation CarriersJAMA, 2017
- Risks of first and subsequent cancers among TP53 mutation carriers in the National Cancer Institute Li‐Fraumeni syndrome cohortCancer, 2016
- Cancer in Fanconi anemia, 1927–2001Cancer, 2003